Skip to content

Study of Osteogenesis Imperfecta Tendon

Study of Osteogenesis Imperfecta Tendon and Ligament: Retrospective and Prospective Assessment.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06065111
Acronym
SOIT
Enrollment
130
Registered
2023-10-03
Start date
2023-09-13
Completion date
2025-06-01
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteogenesis Imperfecta

Keywords

Osteogenesis Imperfecta

Brief summary

Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with fractures and deformities. However, other tissues rich in type I collagen can also be affected, such as teeth or vessel walls. In the literature, several case reports describe tendon ruptures in OI patients, but no original study has really addressed this issue, which is likely to impact the quality of life through a reduction in mobility and pain. Recent work carried out by the investigators shows an alteration of the osteotendinous unit in the osteogenesis imperfecta mouse (oim), a validated model of the most severe form of OI. Consequently, the project aims to study the damage of tendon and ligament in patients suffering from osteogenesis imperfecta.

Detailed description

This project aims to study the damage of tendon and ligament in a cohort of patients suffering from osteogenesis imperfecta. The data collected will be put into perspective with those of our first experimental work on mice. They will also make it possible to complete the specific care of these patients. Indeed, during the anamnesis, particular attention will be paid to the description of tendon-ligament pain in order to propose the most effective treatment for this kind of disorder, mainly in physiotherapy. Prevention work will surely be necessary with patients and caregivers.

Interventions

OTHERstudy tendon damage in osteogenesis imperfecta patients

* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease. * To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease.

Sponsors

Hopital Lariboisière
CollaboratorOTHER
University Hospital, Lille
CollaboratorOTHER
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
CollaboratorOTHER
Université Catholique de Louvain
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* to have an osteogenesis imperfecta

Exclusion criteria

* none, since we want to study different types of osteogenesis imperfecta and consider the effect of age.

Design outcomes

Primary

MeasureTime frameDescription
Tendon stiffnessThroughout the entire study, approximately during 22 monthsTriceps suralis tendon, from zero to infinity, expressed in Newton/mm², a high value indicates a high stiffness

Secondary

MeasureTime frameDescription
Mobility : walking testThroughout the entire study, approximately during 22 monthsTimed-up and go (if walking is possible for the patient)
Grip strength testThroughout the entire study, approximately during 22 monthsDynamometer
Quality of life for childrenThroughout the entire study, approximately during 22 monthsPediatric Quality of Life Inventory
KinesiophobiaThroughout the entire study, approximately during 22 monthsTampa questionnaire
Pain localization and intensity for childrenThroughout the entire study, approximately during 22 monthsface scale
Pain localization and intensity for adultsThroughout the entire study, approximately during 22 monthsvisual analogue scale
Quality of life for adultsThroughout the entire study, approximately during 22 monthsMedical Outcomes Study 36-item Short-Form Health Survey

Countries

Belgium

Contacts

Primary ContactCatherine Behets
catherine.behets@uclouvain.be+3227645245
Backup ContactAntoine Chretien
antoine.chretien@uclouvain.be

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026